Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising drug combo targets rare spine tumor

NCT ID NCT01407198

Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested the safety of combining the drug nilotinib with standard radiation therapy for people with high-risk chordoma, a rare bone tumor. The goal was to find the highest safe dose of nilotinib that could be given alongside radiation without causing severe side effects. Twenty-three participants were enrolled to help determine the best dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

23 people

The number who actually took part.

Start date

Aug 2011

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed chordoma * Considered to have high risk disease * Measurable disease * Life expectancy \> 3 months * Adequate organ function * Able to swallow oral capsules Exclusion Criteria: * Previous treatment with any other tyrosine kinase inhibitor * Previous treatment with radiotherapy to the primary or recurrent chordomas * Impaired cardiac function * Currently receiving treatment with strong CYP3A4 inhibitors * Requires anticoagulation with coumadin * Impaired GI function or GI disease that may significantly alter the absorption of study drug * Acute or chronic pancreatic disease * Known cytopathologically confirmed CNS infiltration * Another primary malignant disease which requires systemic treatment * Acute or chronic liver disease or severe renal disease considered unrelated to the cancer * History of significant congenital or acquired bleeding disorder unrelated to cancer * Major surgery within 4 weeks prior to Day 1 of the study or who have not recovered from prior surgery * Treatment with other investigational agents within 30 days of Day 1 * History of non-compliance to medical regimens * Pregnant or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chordoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chordoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chordoma

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.